Status: Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
This is a Phase 1, two-part, open-label, nonrandomized, dose-escalation and signal-seeking study of CGT6297, evaluating the safety, tolerability, PK, pharmacodynamic (what the drug does to the body), and antitumor activity of CGT6297 in adult participants with advanced solid tumors harboring PIK3CA mutations
Participants needed: 90
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Cogent Biosciences, Inc.Updated: Jul 1, 2026Locations: 4
Eligibility criteria
Phase 1b Cohort 1, participants must have PIK3CA endometrial cancer [+9]
Received small molecule chemotherapy or anticancer therapies or radiotherapy wit... [+6]